Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases

Area of Science:

• Biomedical Science
• Drug Discovery
• Molecular Biology

Background:

• Tissue fibrosis is a major cause of mortality and morbidity globally, lacking approved therapeutic interventions.
• Transforming growth factor (TGF)-β is a critical pro-fibrotic cytokine, presenting a potential therapeutic target.
• Systemic inhibition of TGF-β carries risks due to its diverse biological roles, necessitating targeted approaches.

Purpose of the Study:

• To review the pivotal role of the TGF-β signaling pathway in fibrotic diseases.
• To examine recent advancements in antifibrotic drug development.
• To identify potential therapeutic targets for fibrotic diseases, guiding future research.

Main Methods:

• Literature review of studies on TGF-β signaling in fibrosis.
• Analysis of recent developments in small molecule inhibitors and neutralizing antibodies targeting TGF-β.
• Exploration of emerging therapeutic strategies and targets in fibrotic disease treatment.

Main Results:

• The TGF-β signaling pathway is central to the pathogenesis of various fibrotic conditions.
• Current drug development focuses on selective inhibition of TGF-β signaling to mitigate adverse effects.
• Several novel therapeutic strategies and targets are emerging for fibrosis treatment.

Conclusions:

• Targeting the TGF-β pathway holds promise for treating fibrotic diseases.
• Developing safe and efficient TGF-β inhibitors is crucial for effective fibrosis therapy.
• Further research into specific targets within the TGF-β pathway is warranted to guide the next generation of antifibrotic drugs.